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A noninvasive test is needed to assess the sever-
ity of encephalopathy during fulminant hepatic
failure. This feasibility study was designed to
compare a noninvasive test, brain lactate measure-
ment by magnetic resonance spectroscopy, with
intracranial pressure monitoring in a large animal
model of fulminant hepatic failure. Five dogs
received an intraventricular catheter for intracra-
nial pressure measurement. Liver injury was in-
duced by intravenous bolus of D-galactosamine.
Brain lactate concentrations were determined by
magnetic resonance spectroscopy for up to 48
hours after D-galactosamine administration (t 5 0
hour). A dose of D-galactosamine exceeding 1.5
g/kg resulted in fulminant hepatic failure. Brain
lactate levels increased to G10 mmol/L in the two
dogs that developed severe intracranial hyperten-
sion of G50 mm Hg and sustained cerebral perfu-
sion pressures of F40 mm Hg. Both dogs experi-
enced brain death, 42 and 48 hours after the
administration of D-galactosamine. Brain lactate
concentrations determined by magnetic reso-
nance spectroscopy were in agreement with brain
tissue concentrations of lactate determined by
high-performance liquid chromatography at nec-
ropsy. Plasma lactate concentrations were only
mildly elevated (3.2 and 4.2 mmol/L) at the time of
brain death. Elevated levels of brain lactate are
associated with intracranial hypertension and poor
neurological outcome during fulminant hepatic
failure.
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A noninvasive test is needed to assess the sever-ity of encephalopathy in patients with fulmi-
nant hepatic failure (FHF), including those await-
ing liver transplantation or during treatment with a
bioartificial liver. One possibility is the in vivo
measurement of brain lactate by magnetic reso-
nance spectroscopy (MRS), a relatively new technol-
ogy that has shown promise in the evaluation of
other neurological disorders, including neonatal
asphyxia,1,2 meningitis,2 cardiac arrest,2 head
trauma,2,3 and mitochondrial errors of metabo-
lism.4-6 In pediatric patients with central nervous
system disease, MRS has shown that an elevated
concentration of brain lactate correlated strongly
with poor neurological outcome (long-term disabil-
ity or death).2 MRS has also shown that the level of
brain lactate correlated with the duration of brain
edema and coma in a patient with acute decompen-
sation of maple syrup urine disease.7
Based on these reports with other neurological
disorders, brain lactate by MRS was considered to
be a marker of advanced encephalopathy during
acute liver failure. The current feasibility study was
designed to compare in vivo brain lactate measure-
ment by MRS with intracranial pressure (ICP)
monitoring by intraventricular catheter in a large
animal model of FHF. Cerebral edema, manifest as
intracranial hypertension, is an important cause of
cerebral ischemia during FHF. Because the blood
brain barrier is impermeable to lactate,8 increased
brain lactate is most likely the result of cerebral
ischemia. Therefore, both ICP and brain lactate
were assumed to reflect the extent of cerebral
edema during acute liver failure. Because other
brain metabolites, such as glutamine and gluta-
mate, may contribute to the formation of cerebral
edema,9-13 concentrations of glutamine and gluta-
mate were also determined by MRS in this study.
Materials and Methods
All animals were treated humanely and according to a
protocol approved by the Animal Care and Use Commit-
tee at the University of Minnesota in accordance with
guidelines set forth by the National Academy of Sciences.
Five male dogs, 1–3 years of age and weighing 15–20 kg,
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were conditioned for 4 weeks before use. All animals
were studied under general anesthesia, which included
thiopental induction (15 mg/kg) and inhaled halothane
(0.5%–1.0%), titrated to maintain systolic blood pressure
in a range of 100–130 mm Hg. Intravenous gentamicin
(2 mg/kg) and ticarcillin (50 mg/kg) were administered
at the time of induction. Each dog received a left external
jugular line for administration of maintenance fluid and
D-galactosamine (Sigma Chemical Co., St. Louis, MO),
which was used to induce acute hepatic failure as
described previously by Sielaff et al.14 The dose of
D-galactosamine ranged from 0 to 2.0 g/kg and was
administered as a bolus infusion over 10 minutes,
starting at t50 hours. In four dogs (D-galactosamine
dose, 0.0, 1.0, 1.7, and 2.0 g/kg), maintenance fluids
consisted of lactated Ringer’s solution supplemented
with 5% dextrose and 10 mEq/L KCl at 50 mL/h. A fifth
dog (D-galactosamine dose, 2.0 g/kg) received no dex-
trose in his intravenous maintenance fluids (lactated
Ringer’s solution with 10 mEq/L KCl at 50 mL/h). A
carotid artery line was placed for measurement of sys-
tolic blood pressure (SBP), diastolic blood pressure
(DBP), and mean arterial pressure (MAP) and sampling
of arterial blood. A urethral catheter was placed for
measurement of urine output throughout each experi-
ment. An intraventricular catheter (Ventrix catheter;
Camino NeuroCare, San Diego, CA) was placed in the
left cerebral ventricle for measurement of ICP.
MRS data were acquired on each animal before the
administration of the dose of D-galactosamine (baseline),
at 12, 24, and 36 hours, and at 2–4-hour intervals until
brain death or up to 48 hours. Sessions of data acquisi-
tion lasted 30 minutes and were divided into 10 3-
minute intervals to allow for the correction of small
frequency drifts that were assessed to be ,5 Hz. MRS
data were collected under in vivo conditions using a 9.4
T, 31-cm bore diameter scanner (Varian, Palo Alto, CA).
A 12-cm single-turn surface transmit/receive coil sol-
dered from a series of capacitors (American Technical
Ceramics, Huntington St., NY) was used.15 The volume
for measurement of brain metabolites was set to 1 cm3
and was placed in the right temporal lobe adjacent to the
lateral ventricle on the side contralateral to the ICP
catheter. This site was selected to avoid image signal loss
related to hemorrhagic artifact from the insertion path of
the ICP catheter. Positioning was verified before each
MRS session using fast low-angle shot imaging with a
repetition time of 60 milliseconds, an echo time of 6
milliseconds, and a flip angle of approximately 30°.15
Shimming of the 1 cm3 volume was performed using
Fastmap,16 which resulted in water line widths between
12 and 20 Hz and creatine line widths between 8 and 16
Hz (i.e., 0.02 and 0.04 ppm). Spectroscopy was based on
a modification of stimulated echo acquisition mode
using a repetition time of 3 seconds, echo time of 20
milliseconds, and a mixing time (TM) of 36 millisec-
onds.17-19 Special care was taken to minimize eddy
current effects, which were estimated in phantoms to
contribute ,3 Hz to the peak width.
Data processing consisted of at least fourfold zero-
filling (zero-padding) to ensure proper digitization of the
peak shape, 5 Hz exponential multiplication and manual
zero-order and first-order phase correction. Peak analy-
sis was performed using Lorentzian peak fitting of lactate
(1.33 ppm), N-acetyl-aspartate (NAA) (2.02 ppm), gluta-
mate (2.37 ppm), and glutamine (2.46 ppm) in the range
from 1.0 to 2.5 ppm. The millimolar concentrations of
lactate, glutamine, and glutamate were determined by
comparison of peak area with NAA, which was assumed
to be stable at 10 mmol/L.20
Vital signs (blood pressure, heart rate, ICP, and urine
output) were recorded at baseline and then every 2
hours. Arterial blood gases were obtained at 6-hour
intervals and 30 minutes after ventilator changes. Venti-
lation was adjusted to maintain arterial PCO2 at 35–40
mm Hg. Arterial blood samples were also obtained before
the administration of the dose of D-galactosamine (t50
hours), at t512 hours, t524 hours and then at 6-hour
intervals. Blood samples were analyzed for electrolytes,
aspartate aminotransferase, ammonia, lactate, and inter-
national normalization ratio in the clinical laboratory at
the University of Minnesota. At the completion of each
experiment, animals were killed by pentobarbital-
potassium overdose. Necropsy included gross examina-
tion of the brain and liver. Liver sections were placed in
formalin, processed in the usual fashion, and examined
microscopically after staining with hematoxylin-eosin.
Brain tissue from the right cortex was snap-frozen
and stored at 280°C for lactate analysis. Briefly, brain
tissue was weighed by analytical balance (model HL 52;
Mettler Instrument Corp., Highstown, NJ) and trans-
ferred to a microhomogenizer (part no. MH-10; Micro-
Metric Instruments Co., Tampa, FL) containing 500 µL
of ice-cold deionized water. After 60 seconds of homog-
enization, the contents of the homogenizer were soni-
cated at room temperature for 6 minutes and then
transferred to a 2-mL microfuge tube. Homogenizers
were rinsed with two aliquots of 500 µL deionized water
to prevent loss of tissue residue. After 2 minutes of
microfugation at 12,000 rpm, samples were passed
across a 0.20-µm polytetrafluoroethylene filter. Lactate
concentrations were determined from filtered samples by
a standardized kit (Sigma Chemical Co.).
Results
The extent of liver injury and encephalopathy
varied directly with the dose of D-galactosamine
(0.0, 1.0, 1.7, and 2.0 g/kg). Liver injury was
determined by histological examination of liver
tissues obtained at necropsy (Fig. 1), along with
two (international normalization ratio and aspar-
tate aminotransferase) biochemical markers of liver
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function (Table 1). Encephalopathy was deter-
mined from intraventricular measurements of ICP
and gross examination of the brain at autopsy. A
dose of D-galactosamine of 1.7–2.0 g/kg caused
sustained intracranial hypertension (ICP of .50
mmHg) and brain death within 48 hours, as
summarized in Table 1. Brain death was defined as
the simultaneous decrease in SBP and ICP after a
progressive increase in ICP. Figure 2 shows that
cerebral perfusion pressure (CPP; CPP 5 MAP 2
ICP) decreased steadily before brain death in both
dogs that were administered lethal doses of D-
galactosamine, but CPP remained stable at a lower
dose of D-galactosamine (0.0 and 1.0 g/kg).
Figure 1. Histologic appearance of liver tissue obtained at necropsy. A dose-dependent extent of liver
injury after an intravenous bolus of D-galactosamine. (A) Normal dog liver from control (D-galactosamine,
0.0 g/kg). (B) Rare necrotic hepatocytes and mild lobular disarray 48 hours after administration of 1.0
g/kg D-galactosamine. (C) Scattered foci of necrosis without an acute inflammatory response 46 hours
after administration of 2.0 g/kg D-galactosamine. (D) Increased hepatocellular necrosis, hepatocyte
drop-out, and nuclear debris at the time of hypoglycemic death. This dog also was administered 2.0 g/kg
D-galactosamine, but maintenance fluids contained no supplemental glucose.
Table 1. Dose-Dependent Effect of D-Galactosamine on Liver Failure and Encephalopathy
Dose (g/kg) ASTmax (U/L) INRmax ICPmax (mm Hg) Outcome
None 17 1.1 18 Stable survival
1.0 287 1.5 27 Mild liver injury
1.7 5745 .10 60 Brain death at 48 h
2.0 4100 .10 74 Brain death at 42 h
Abbreviations: max, maximum value obtained during each experiment; AST, aspartate aminotransferase; INR,
international normalization ratio.
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The control dog, which was not administered
D-galactosamine, showed no signs of cerebral
edema. There was mild edema of the brain in the
dog that was administered 1.0 g/kg of D-galactos-
amine. The mild edema may have been the result of
trauma during placement of the ICP catheter
because the right hemisphere, contralateral to the
ICP catheter, appeared less edematous. Both dogs
that experienced severe intracranial hypertension
showed marked edema and swelling of their brains
and died from apparent brain stem herniation.
Thirty-minute sessions, divided into 10 3-
minute intervals, were used for the acquistion of
MRS data. Only small frequency drifts were ob-
served during each 30-minute session, as shown in
Fig. 3. A sharp increase in brain lactate was
measured by MRS during the development of FHF
induced by D-galactosamine. The increase in brain
lactate preceded brain death and coincided with
the decrease in CPP. Sequential MRS spectra in Fig.
4 show the increase in brain lactate after a lethal
dose of D-galactosamine (2.0 g/kg). Brain lactate
levels remained high after brain death, character-
ized by a sudden and progressive decrease in ICP as
shown in Fig. 5. Brain lactate concentrations were
also determined from right hemispheric tissue that
corresponded to the area of MRS sampling. Table 2
shows that final concentrations of lactate in the
brain were similar by MRS and tissue assay. These
final concentrations of lactate were much higher
than plasma concentrations of lactate obtained
immediately before necropsy (Table 2).
Concentrations of glutamine, glutamate, and
NAA were determined in the brain by MRS through-
out each experiment. There were no sustained or
reproducible trends in the concentration of brain
glutamine or brain glutamate during the develop-
ment of FHF (data not shown). The concentration
Figure 2. CPP decreased about 30 hours after a
lethal dose of D-galactosamine (D-Gal) but re-
mained stable at lower doses. Brain death oc-
curred about 4 hours after CPP decreased to F40
mm Hg in both dogs with advanced FHF. s,
Control (0.0 g/kg); m, D-galactosamine (1.0 g/kg); j,
D-galactosamine (1.7 g/kg); d, D-galactosamine
(2.0 g/kg).
Figure 3. Representative MRS data obtained dur-
ing one 30-minute session. Ten spectra were
collected at 3-minute intervals, (A) individually
and (B) superimposed.
Figure 4. Sequential MRS spectra during the de-
velopment of FHF in the dog. An increase in brain
lactate (Lac) was observed over time (23, 39, and
43 hours) in the same dog after administration of
D-galactosamine (2.0 g/kg) at t 5 0 hours. Other
chemical species that were identified by 1H-
proton spectroscopy at a field strength of 9.4 T
are labeled and include choline (Cho), creatine
(Cr), glutamine (Gln), glutamate (Glu), and NAA.
NAA levels were stable until the time of brain
death.
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of NAA remained stable with F5% fluctuation in
standard deviation of the mean peak area of NAA
(2293.3 6 93.1 arbitrary units) during the develop-
ment of FHF (dose, 2.0 g/kg).
A fifth dog was administered no supplemental
dextrose and experienced severe liver injury (maxi-
mum aspartate aminotransferase, 13,782 U/L) and
sudden death 44 hours after administration of
D-galactosamine (dose, 2.0 g/kg). Of importance,
death occurred without intracranial hypertension
(ICP of 18 mm Hg) and with a normal brain lactate
(,2 mmol/L). This dog was the only subject to
develop hypoglycemia and died with a blood
glucose of ,20 mg/dL.
Discussion
The diagnosis of hepatic encephalopathy is made
from a combination of clinical and laboratory
findings, which include neurological deficits and
evidence of hepatocyte damage. Unfortunately, these
findings are nonspecific predictors of patient sur-
vival. Cerebral edema and brainstem herniation,
significant contributors to mortality in acute liver
failure, are poorly estimated by physical examina-
tion or standard liver function tests.21,22 Computed
tomography scan and magnetic resonance imaging
of the head are useful to exclude other etiologies of
altered mental status.23 Unfortunately, intracranial
changes may occur late in FHF and are difficult to
identify by imaging studies.24 Epidural, subdural,
and intraventricular catheters are helpful in guid-
ing therapy to prevent brainstem herniation be-
cause they are direct measures of ICP.24 Intracranial
monitoring devices are invasive and problematic
during acute liver failure, especially in the setting
of coagulopathy.25 In at least one study, significant
morbidity (intracranial bleeding, 22%) and mortal-
ity (death, 9%) resulted from ICP monitoring of
patients with FHF.26 A safer, noninvasive method of
assessing cerebral edema in FHF is therefore needed.
MRS is a relatively new technology that has
great potential in the evaluation of patients with
central nervous system disorders, including en-
cephalopathy in liver disease.10,12,27-34 The concen-
trations of many cerebral metabolites, such as
glutamine, glutamate, and lactate, can be measured
in the brain under in vivo conditions with MRS
(see Fig. 4).
In the current study, we report a sharp increase
in brain lactate that occurred shortly before brain
death in dogs with advanced FHF. The sharp
increase in brain lactate was associated with sus-
tained intracranial hypertension (Fig. 5) and cere-
bral hypoperfusion (Fig. 2) and appeared to be
prognostic of brainstem herniation. As required by
the Animal Care and Use Committee at the Univer-
sity of Minnesota, dogs were under general anesthe-
sia during the development of FHF. As a result, a
neurological examination was not possible. There-
fore, brain death was defined as the simultaneous
decrease in SBP and ICP after a progressive increase
in ICP.
Elevated concentrations of brain lactate have
already been shown to correlate with outcome in
children with a variety of central nervous system
disorders. In one study, elevated levels of brain
Figure 5. Graph of ICP and brain lactate concen-
tration versus time after infusion of D-galactos-
amine (D-gal; 2.0 g/kg) and the induction of FHF in
the dog. A sharp increase in brain lactate pre-
ceded the maximum ICP at 42 hours. An abrupt
decrease in SBP coincided with the maximum ICP
and was interpreted as the time of brainstem
herniation and brain death. Plasma lactate concen-
trations remained relatively stable at the time of
brain death and suggested that lactate production
occurred centrally. Elevated brain lactate appears
to be a marker of intracranial hypertension and
cerebral hypoperfusion. h, ICP (in mm Hg); r,
brain lactate; X, plasma lactate.
Table 2. Comparison of Final Lactate
Concentrations
Dose of
D-Galactosamine
(g/kg)
Final Lactate Concentration
Plasma
(mmol/L)
Brain-MRS
(mmol/L)
Brain-Tissue
(mmol/L)
None 0.7 ,2 mmol/L 1.3
1.0 1.2 ,2 mmol/L 1.4
1.7 4.2 11.8 18.0
2.0 3.2 28.3 27.7
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lactate correlated significantly (P , .001) with seri-
ous long-term disability and death in a group of 36
pediatric patients with acute central nervous sys-
tem injuries.2 Mildly elevated concentrations of
brain lactate were associated with reversible en-
cephalopathy in a 14-year-old boy with Reye’s
syndrome35 and a patient with acute decompensa-
tion of maple syrup urine disease.7
A proposed explanation for brain lactate produc-
tion and brain death during FHF induced by
D-galactosamine is outlined in Fig. 6. According to
this paradigm, acute liver failure triggers both
cytotoxic and/or vasogenic changes in the brain
that result in the formation of edema.36 The under-
lying cause of brain edema in acute liver failure
remains unresolved. It has been suggested that
glutamine may accumulate in astrocytes during
hyperammonemia of liver failure and serve as a
primary osmole in causing astrocyte swelling and
the formation of brain edema.37 Evidence in sup-
port of glutamine serving as an organic osmolyte
was obtained in hyperammonemic animals38 or
animals after total hepatectomy39 or portocaval
anastomosis.13 In our study of drug-induced FHF,
the concentration of brain glutamine increased to
8.3 mmol/L (see Fig. 4), which is within 100%
variation of the basal concentration of brain gluta-
mine. The less than expected increase in brain
glutamine may highlight potential differences be-
tween the D-galactosamine model and other mod-
els of hepatic encephalopathy.
Our results suggest that lactate production is
increased in the brain after D-galactosamine admin-
istration and the development of FHF. In fact, brain
lactate concentrations in the range of 10–25 mmol/L
were detected by MRS before brain death. These
concentrations of brain lactate might be expected
to have a pathogenic or osmotic effect on further
formation of cerebral edema.40 Therefore, along
with serving as a marker of anaerobic metabolism,
lactate may serve as a secondary osmole and
contribute to the formation of cerebral edema and
brainstem herniation. In support of this hypothesis
is the observation that ICP and brain lactate increased
at similar rates shortly before brain death. Also in
support of this hypothesis is the absence of intracra-
nial hypertension and the absence of increased
brain lactate in the hypoglycemic dog (Fig. 1D)
that died 44 hours after infusion of D-galactos-
amine. Production of lactic acid is not possible
during hypoglycemia because of glucose (substrate)
deficiency.8 Conversely, in children with central
nervous system disorders, hyperglycemia was asso-
ciated with increased brain lactate when compared
with similar patients with normoglycemia.2
Lactic acidosis resulting from cerebral ischemia
and increased anaerobic glycolysis may also cause
lysosomal instability and cerebral damage by the
activation of lysosomal enzymes.41 Alternatively, it
has been proposed that lactate accumulation dur-
ing liver failure is the result of ammonia-induced
inhibition of the malate-aspartate shuttle and/or
inhibition of tricarboxylic acid cycle flux in the
brain.42 Of note, in vivo 13C MRS studies suggest
that the rate of the tricarboxylic acid cycle is not
significantly altered during ammonia infusion.43
The anesthetized model of FHF, first described
by Sielaff et al,14 was used in this study. This dog
model provided a large brain for intraventricular
catheter placement and MRS data acquisition. FHF,
including significant intracranial hypertension and
brain death within 48 hours, was reproducible after
the administration of 1.7 and 2.0 g/kg D-galactos-
amine, which was greater than the dose (1.0 g/kg)
used to produce liver failure by Sielaff et al. We
found that brain death did not occur within 48
hours at doses of D-galactosamine of ,1.7 g/kg.
These findings are in agreement with the study of
Diaz-Buxo et al.44 No signs of endotoxic shock
were observed in our study because SBP remained
.100 mm Hg before brain death. Intracranial
hypertension was an important finding in our
study, although no evidence of edema was observed
on gross or microscopic examination of the brain in
the study of Diaz-Buxo et al.44 A higher dose of
1.7–2.0 g/kg of D-galactosamine may be needed in
the dog for the formation of cerebral edema. The
development of cerebral edema and intracranial
hypertension after infusion of D-galactosamine is
Figure 6. Proposed explanation of brain death in
D-galactosamine–induced FHF.
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supported by past reports using rats36,45,46 and
rabbits.47,48
Although the current study was conducted in an
experimental facility at 9.4 T, observations made in
this study regarding brain lactate are transferable to
the clinical setting. Namely, identification of the
lactate peak at 1.33 ppm is currently possible on
clinical MRS scanners (1.5 T) provided care is
taken to eliminate contributions from extraneous
lipid resonances. Proton spectra of brain lactate at
1.5 T have been reported in a case of Reye’s
syndrome35 and in a variety of other diseases with
neurological manifestations.1-7 Unfortunately, un-
ambiguous separation of the glutamine/flutamate
complex (2.2–2.5 ppm) is not possible at 1.5 T. It
was for this reason that the current study was
performed at 9.4 T.
We concluded from this feasibility study that the
measurement of brain lactate by MRS is a noninva-
sive test of advanced encephalopathy during acute
hepatic failure. In particular, our data suggest that
brain death is likely in the setting of an increasing
brain lactate during FHF. It cannot be determined
from this feasibility study whether brain lactate is
also a marker of reversible brain injury because
both animals died after development of elevated
brain lactate and because therapies such as osmotic
diuretics, hyperventilation, or a bioartificial liver
were not attempted to lower ICP. This study
supports the role of MRS in the evaluation of
encephalopathy during FHF.
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